Cytek Biosciences, Inc. CTKB
5.40 USD -0.48 (-8.16%)
At closeNov 6, 2026, 6:09 AM EST
5.35 -0.05 -0.93%
Pre-market · Nov 6, 6:09 AM ET
5.38 Day range 6.01
3.31 52-week range 6.34
- YTD
- +6.93%
- 1 year
- +34.66%
Financial health
Altman Z-Score
3.96 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 3
Valuation
P/E -9.7×
FY 2019 5y median -9.7× FY 2025
P/S 3.2×
FY 2019 5y median 6.4× FY 2025
P/B 1.9×
FY 2019 5y median 3.1× FY 2025
P/FCF -73.6×
FY 2019 5y median 38.8× FY 2025
EV/EBITDA -33.2×
FY 2019 5y median 115× FY 2025
EV/Sales 2.9×
FY 2019 5y median 5.6× FY 2025
FCF Yield -1.4%
FY 2019 5y median 0.0% FY 2025
Profitability
Gross Margin 51.8%
FY 2019 5y median 56.7% FY 2025
Operating Margin -20.0%
FY 2019 5y median -10.2% FY 2025
Net Margin -33.0%
FY 2019 5y median -3.0% FY 2025
ROE -19.5%
FY 2019 5y median -1.5% FY 2025
ROIC -10.3%
FY 2019 5y median -4.7% FY 2025
ROA -14.4%
FY 2019 5y median -1.2% FY 2025
Growth (YoY)
Revenue 0.5%
FY 2019 FY 2025
Operating Income -96.8%
FY 2019 FY 2025
EPS (diluted) -1028.0%
FY 2019 FY 2025
Free Cash Flow -140.1%
FY 2019 FY 2025
Financial Health
Current Ratio 5.0×
FY 2019 5y median 7.0× FY 2025
Quick Ratio 4.4×
FY 2019 5y median 5.9× FY 2025
Debt / Equity 0.1×
FY 2019 5y median 0.0× FY 2025
Net Debt / EBITDA 3.9×
FY 2019 5y median -17.1× FY 2025
Interest Coverage -85.2×
FY 2019 5y median -0.7× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31